Search results for " Angioedema"

showing 10 items of 121 documents

Development of the Angioedema Control Test—A patient‐reported outcome measure that assesses disease control in patients with recurrent angioedema

2019

Background Recurrent angioedema (AE) is an important clinical problem in the context of chronic urticaria (mast cell mediator-induced), ACE-inhibitor intake and hereditary angioedema (both bradykinin-mediated). To help patients obtain control of their recurrent AE is a major treatment goal. However, a tool to assess control of recurrent AE is not yet available. This prompted us to develop such a tool, the Angioedema Control Test (AECT). Methods After a conceptional framework was developed for the AECT, a list of potential AECT items was generated by a combined approach of patient interviews, literature review and expert input. Subsequent item reduction was based on impact analysis, inter-it…

0301 basic medicinemedicine.medical_specialtyImmunologyValidityContext (language use)Bradykinin03 medical and health sciences0302 clinical medicinemedicineContent validityHumansImmunology and AllergyPatient Reported Outcome MeasuresAngioedemaRetrospective StudiesRecallAngioedemabusiness.industryReproducibility of Resultsmedicine.diseaseDisease control030104 developmental biology030228 respiratory systemHereditary angioedemaPhysical therapyPatient-reported outcomemedicine.symptombusinessAllergy
researchProduct

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme …

2020

Bradykinin (BK)-mediated angioedema (AE) states are rare acquired or hereditary conditions involving localized edema of the subcutaneous and submucosal tissues. Citrated plasma from healthy volunteers or patients with hereditary angioedema (HAE) with normal level of C1-inhibitor (C1-INH) was used to investigate pathways of BK formation and breakdown relevant to AE physiopathology. The half-life of BK (100 nM) added to normal plasma was 34 s, a value that was increased ~12-fold when the angiotensin converting enzyme (ACE) inhibitor enalaprilat (130 nM) was added (enzyme immunoassay measurements). The BK half-life was similarly increased ~5-fold following 2 daily oral doses of enalapril malea…

0301 basic medicinemedicine.medical_specialtykallikreinsPlasminBradykininTissue plasminogen activator03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineB2 receptorsOriginal ResearchplasminFactor XIIlcsh:R5-920tissue plasminogen activatorAngioedemabiologyhereditary angioedema with normal C1 inhibitor levelAngiotensin-converting enzymeGeneral MedicineKallikreinmedicine.disease030104 developmental biologyEndocrinology030228 respiratory systemchemistryHereditary angioedemabiology.proteinMedicinemedicine.symptombradykininlcsh:Medicine (General)medicine.drugFrontiers in Medicine
researchProduct

Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels

2016

Background Hereditary angioedema with normal C1 inhibitor levels (HAE-N) is associated with a Factor XII mutation in 30% of subjects; however, the role of this mutation in the pathogenesis of angioedema is unclear. Objective We sought evidence of abnormalities in the pathways of bradykinin formation and bradykinin degradation in the plasma of patients with HAE-N both with and without the mutation. Methods Bradykinin was added to plasma, and its rate of degradation was measured by using ELISA. Plasma autoactivation was assessed by using a chromogenic assay of kallikrein formation. Plasminogen activator inhibitors (PAIs) 1 and 2 were also measured by means of ELISA. Results PAI-1 levels varie…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentImmunologyBradykinin030204 cardiovascular system & hematologyArticleC1-inhibitor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineFibrinolysismedicineImmunology and AllergyFactor XIIAngioedemabiologybusiness.industryKallikreinmedicine.disease030104 developmental biologyEndocrinologychemistryPlasminogen activator inhibitor-1Hereditary angioedemabiology.proteinmedicine.symptombusinessJournal of Allergy and Clinical Immunology
researchProduct

Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation

2020

Background Hereditary angioedema (HAE) is a potentially fatal disorder resulting in recurrent attacks of severe swelling. It may be associated with a genetic deficiency of functional C1 inhibitor or with normal C1 inhibitor (HAEnCI). In families with HAEnCI, HAE-linked mutations in the F12, PLG, KNG1, ANGPT1, or MYOF genes have been identified. In many families with HAEnCI the genetic cause of the disease is currently unknown. Objective The aim of this study was to identify a novel disease-linked mutation for HAEnCI. Methods The study methods comprised whole exome sequencing, Sanger sequencing analysis, pedigree analysis, bioinformatic analysis of the mutation, and biochemical analysis of p…

Adult0301 basic medicineImmunologyMutantGene mutationBiologyC1-inhibitor03 medical and health sciencessymbols.namesakechemistry.chemical_compound0302 clinical medicineExome SequencingmedicineHumansImmunology and AllergyExome sequencingAged 80 and overSanger sequencingGeneticsAngioedemas HereditaryHeparan sulfateMiddle Agedmedicine.disease030104 developmental biology030228 respiratory systemchemistryMutationMutation (genetic algorithm)Hereditary angioedemasymbolsbiology.proteinFemaleSulfotransferasesJournal of Allergy and Clinical Immunology
researchProduct

Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy

2003

Abstract Purpose Recurrent angioedema, characterized by skin swelling, colicky attacks of abdominal pain, and life-threatening laryngeal edema, can be either hereditary or acquired. According to anecdotal reports, it may be associated with use of oral contraceptives and hormone replacement therapy. We investigated potential interactions between these medications and various types of recurrent angioedema in a large cohort of women. Methods Women with recurrent angioedema (n = 516) underwent a thorough medical evaluation. They were then classified by type of angioedema, using standard criteria. Results Of the 516 women, 228 (44%) had used oral contraceptives or hormone replacement therapy, in…

AdultAbdominal painmedicine.medical_specialtyHormone Replacement TherapyPopulationRisk AssessmentSeverity of Illness IndexCohort StudiesAge DistributionRecurrenceimmune system diseasesHumansMedicineHereditary Angioedema Type IIIcardiovascular diseasesAngioedemaRisk factorskin and connective tissue diseaseseducationAgedRetrospective Studieseducation.field_of_studyAngioedemabusiness.industryfood and beveragesRetrospective cohort studyGeneral MedicineMiddle AgedPrognosisDermatologyAbdominal PainSurgeryTransgender hormone therapyFemalemedicine.symptombusinessComplicationContraceptives OralThe American Journal of Medicine
researchProduct

Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema

2005

BACKGROUND: Abdominal edema attacks in patients with hereditary angioedema are often extremely painful, associated with vomiting and diarrhea, and have a high potential for causing recurrent disability of the patient. STUDY DESIGN AND METHODS: Intraindividual comparison of retrospective data in 75 hereditary angioedema patients comprising 4,834 abdominal attacks treated with C1 inhibitor concentrate versus 17,444 untreated abdominal attacks. RESULTS: The mean duration of abdominal attacks was 92.0 hours (SD, 40.8 hr) when untreated compared to 39.9 hours (SD, 30.0 hr) when treated. Patients reported a mean maximal pain score of 8.6 (SD, 1.7; range, 1-10) for untreated attacks compared to 4.…

AdultDiarrheaAbdominal painTime FactorsAdolescentVomitingHypovolemiaImmunologyUnconsciousnessComplement C1 Inactivator ProteinsDrug Administration ScheduleInjectionsC1-inhibitorEcallantideHypovolemiaEdemamedicineHumansImmunology and AllergyAngioedemaChildAdverse effectSerpinsRetrospective StudiesDose-Response Relationship Drugbiologybusiness.industryInfantHematologymedicine.diseaseAbdominal PainTreatment OutcomePatient SatisfactionChild PreschoolAnesthesiaHereditary angioedemaVomitingbiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinBed Restmedicine.drugTransfusion
researchProduct

Hereditary angioedema with a mutation in the plasminogen gene

2017

Background Hereditary angioedema (HAE) with normal C1-INH (HAEnCI) may be linked to specific mutations in the coagulation factor 12 (FXII) gene (HAE-FXII) or functional mutations in other genes that are still unknown. We sought to identify and characterize a hitherto unknown type of HAE with normal C1-INH and without mutation in the F12 gene. Methods The study comprised analysis of whole-exome sequencing, Sanger sequencing, and clinical data of patients. Results We detected a mutation in the plasminogen (PLG) gene in patients with HAEnCI. The mutation c.9886A>G was located in exon 9 leading to the missense mutation p.Lys330Glu (K330E) in the kringle 3 domain of the PLG protein. The mutation…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyAdolescentImmunologyMutation MissenseGene mutationBiologyYoung Adult03 medical and health sciencesExonsymbols.namesake0302 clinical medicineGermanyExome SequencingmedicineHumansImmunology and AllergyMissense mutationChildExome sequencingAgedSanger sequencingAngioedemas HereditaryAutosomal dominant traitPlasminogenMiddle Agedmedicine.disease030104 developmental biology030228 respiratory systemChild PreschoolMutationMutation (genetic algorithm)Hereditary angioedemasymbolsFemaleAllergy
researchProduct

Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency.

2012

Background Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is characterized by relapsing skin swellings, abdominal pain attacks, and, less frequently, potentially life-threatening laryngeal attacks. Objective This study determined the mortality of patients with and without the diagnosis of HAE-C1-INH and analyzed fatal laryngeal attacks. Methods A cohort of 728 patients from 182 families with HAE-C1-INH was evaluated for death cases by analyzing pedigrees. Detailed information on fatal laryngeal attacks in 36 patients was obtained by questioning relatives and treating physicians. Results Of the 214 patients who had died, 70 asphyxiated during a laryngeal attack. Mortality …

AdultMaleAbdominal painPediatricsmedicine.medical_specialtyTime FactorsC1 inhibitor deficiencyImmunologyLanadelumabAsphyxiamedicineImmunology and AllergyHumansAgedRetrospective StudiesAged 80 and overAngioedemaHereditary Angioedema Types I and IIbusiness.industryHigh mortalityRetrospective cohort studyMiddle Agedmedicine.diseaseAnesthesiaCohortHereditary angioedemaFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinThe Journal of allergy and clinical immunology
researchProduct

Upregulation of cytokines and IL-17 in patients with hereditary angioedema

2013

AdultMaleAdolescentClinical BiochemistryYoung AdultText miningDownregulation and upregulationmedicinecytokineHumansIn patientChildAgedbusiness.industryBiochemistry (medical)Interleukin-17Angioedemas HereditaryGeneral MedicineMiddle Agedmedicine.diseasehereditary angioedemaUp-RegulationIL-17Th 17Hereditary angioedemaImmunologyMutationCytokinesFemaleInterleukin 17businessComplement C1 Inhibitor Protein
researchProduct

Hereditary angioedema in a single family with specific mutations in both plasminogen and SERPING1 genes

2019

BACKGROUND Hereditary angioedema (HAE) is a group of genetic diseases characterized by recurrent, painful and potentially lethal tissue swelling. The most common form results from mutations in the SERPING1 gene, leading to reduced function of complement 1 inhibitor (C1-INH). Rarer forms with normal C1-INH may arise from mutations in the coagulation factor F12 gene, but mostly the genetic background is unknown. Recently, a novel HAE mutation in the plasminogen (PLG) gene was shown. PATIENTS AND METHODS We analyzed the various clinical manifestations of HAE in 14 related patients using clinical data, biochemical analysis for C1-INH and C4 as well as gene sequencing. RESULTS Patients' symptoms…

AdultMaleAdolescentMutation MissenseDermatologymedicine.disease_causeYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineTonguemedicineHumansFamilyChildGeneSingle familyMutationGastrointestinal tractbusiness.industryAngioedemas HereditaryPlasminogenMiddle Agedmedicine.diseasePhenotype3. Good healthPhenotypemedicine.anatomical_structureCoagulationChild PreschoolMutationHereditary angioedemaImmunologyFemalebusinessComplement C1 Inhibitor ProteinJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct